Crispr Therapeutics AG (GB:0VRQ)
LSE:0VRQ
Holding GB:0VRQ?
Track your performance easily

Crispr Therapeutics AG (0VRQ) Financial Statements

5 Followers

Crispr Therapeutics AG Financial Overview

Crispr Therapeutics AG's market cap is currently ―. The company's EPS TTM is $-3.227; its P/E ratio is -14.39; Crispr Therapeutics AG is scheduled to report earnings on October 30, 2024, and the estimated EPS forecast is $-1.42. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 517.00K$ 504.00K$ 200.00M-$ 70.00M
Gross Profit$ 517.00K$ 504.00K$ 180.00M-$ 70.00M
EBIT$ -125.12M$ -68.90M$ 69.58M$ -111.74M$ -76.82M
EBITDA$ -120.28M$ -64.07M$ 74.48M$ -106.81M$ -71.86M
Net Income Common Stockholders$ -126.41M$ -116.59M$ 89.35M$ -65.31M$ -77.74M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 2.00B$ 2.11B$ 1.69B$ 1.74B$ 1.77B
Total Assets$ 2.34B$ 2.44B$ 2.23B$ 2.09B$ 2.20B
Total Debt$ 231.30M$ 234.93M$ 238.63M$ 241.59M$ 245.18M
Net Debt$ -1.77B$ -1.87B$ -1.46B$ -1.50B$ -1.52B
Total Liabilities$ 358.90M$ 355.08M$ 346.77M$ 359.04M$ 380.99M
Stockholders Equity$ 1.98B$ 2.08B$ 1.88B$ 1.73B$ 1.82B
Cash Flow-
Free Cash Flow$ -96.29M$ 109.03M$ -96.81M$ -41.97M$ -136.80M
Operating Cash Flow$ -95.58M$ 109.75M$ -96.07M$ -39.86M$ -133.25M
Investing Cash Flow$ -126.91M$ -97.80M$ -81.45M$ 121.35M$ 216.92M
Financing Cash Flow$ -466.00K$ 305.93M$ 38.94M$ 1.56M$ 16.77M
Currency in USD

Crispr Therapeutics AG Earnings and Revenue History

Crispr Therapeutics AG Debt to Assets

Crispr Therapeutics AG Cash Flow

Crispr Therapeutics AG Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis